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Protective Effect of Spironolactone on Endothelial-to-Mesenchymal Transition in HUVECs via Notch Pathway

Introduction
The transdifferentiation and generation of myofibroblasts and fibroblasts, is associated with organism proliferation derived from cell apoptosis, necrosis and intercellular transformation in the whole life cycle of mammals. Fibroblasts and myofibroblasts can produce a mass of extracellular matrix (ECM) by activating numerous biological mediators; partial fibroblast cells can transform into myofibroblasts and secrete the characteristic α-smooth muscle actin (α-SMA) alone with overexpression of large amounts of collagen matrix. This continuous secretion status can involve the whole fibrosis process and aggravate fibrosis. Many studies have focused on the biochemical mechanism of the epithelial-to-mesenchymal (EMT) transition and endothelial-to-mesenchymal transition (EndMT), the two basic origins of fibroblasts or myofibroblasts in most fibrosis-related diseases, such as cardiac fibrosis, renal fibrosis, pulmonary fibrosis and hepatic fibrosis [1, 2] . The EndMT progress can be demonstrated by specific biochemical changes, including decreased expression of endothelial makers, mainly VE-cadherin, CD31, von Willibrand factor (vWF), and increased expression of mesenchymal markers such as vimentin, matrix metalloproteases (MMPs), fibroblast-specific protein 1 (FSP-1), fibronectin and α-SMA [3, 4] .
It is well known that TGF-β is the most important mediator that increases the synthesis of matrix proteins and decreases the production of matrix metalloproteinase during fibrosis [5] . TGF-β signals through transmembrane receptors, which activate Smad2/3 phosphorylation: in turn, the phosphorylated Smad2/3 complex translocate into the nucleus, where it induces the expression of pro-fibrotic target genes [6, 7] .
It is known that the Notch signaling pathway, conserved during evolution, mediates signal transduction between neighboring cells and plays a crucial role in cell proliferation, transdifferentiation and apoptosis. Notch signaling occurs in a highly localized manner by interacting with neighboring cells. When a ligand binds to the Notch receptor, Notch undergoes two proteolytic cleavage events: it liberates the Notch intracellular domain to enter the nucleus, where it binds to the transcription factor RBPJK/CBF1/Su(H) and converts it from a repressor to an activator for target genes, including the Hes and Hey family genes [8] . The Notch signal pathway has attracted much attention in research into fibrosis formation and collagen regeneration. In detecting the relevant signal molecules of the Notch pathway in fibrotic tissue, the downstream transcription factor Hes1 was found downregulated and the ligand Jag1 upregulated [9] . Similar results were observed in vivo. In a mouse model with the Notch signal pathway effectively blocked, α-SMA protein expression and collagen staining was increased significantly. The level of TGF-β, which acts as a mediator to induce EndMT, was increased [10] . Furthermore, Notch signaling can contribute to EndMT in both tumor progression and cardiac development [4] . Notch signaling functions in the TGF-β-mediated EndMT that occurs during endocardial cushion formation and myocardial fibrosis [11, 12] .
Studies illustrate activation of the renin-angiotensin-aldosterone system (RAAS) is a risk factor for the development of fibrosis [13, 14] . Spironolactone is the most common aldosterone receptor antagonist used to pharmacologically block actions of aldosterone and for treatment of congestive heart failure, liver cirrhosis and hypertension. It competitively inhibits the binding of aldosterone to the mineralocorticoid receptor [15] . Spironolactone reduced the combined endpoint of death or hospitalization for heart failure in nonAfrican Americans as compared with African Americans; hyperkalemia was lessened and hypokalemia increased [16] . As well, spironolactone improved cardiac remodeling by reducing proinflammatory cytokine levels and inhibiting TGF-β and R-Smads expression [17] .
We examined TGF-β inducing EndMT in primary cultured human umbilical vein endothelial cells (HUVECs) and possible blockage by spironolactone to investigate the morphologic and functional changes. As well, we determined whether the Notch pathway is involved in the EndMT-driven fibrosis. 
Material and Methods
R gents and antibodies ea
Reagents of spironolactone and Hoechst 33342 were from Sigma (St. Louis, MO, USA). DyLight 488 goat anti-rabbit IgG (H+L) and DyLight 594 goat anti-mouse IgG (H+L) were from Molecular Probes (Life Technologies, USA). Antibodies for rabbit monoclonal anti-vimentin, mouse monoclonal anti-CD31 and anti-Notch1 were from Cell Signaling Technology (Cst, Beverly, MA, USA). γ-Secretase inhibitor N-3,5-difluorophenyl acetyl-Lalanyl-2-phenylglycine-1,1-dimethylethyl ester (DAPT) and recombinant human TGF-β were from Roche (Indianapolis, IN, USA). Anti-vWF antibody was from Abcam (Cambridge, MA, USA). Anti-β-actin was from Bioworld Technology (Nanjing, China).
Cell culture and treatment
The First Affiliated Hospital of Wenzhou Medical University. Primary HUVECs were obtained from umbilical cords of randomly selected healthy mothers delivering at the First Hospital affiliated with Wenzhou Medical University after perfusion of umbilical cords with 0.05% trypsin-0.03% EDTA (Invitrogen) for 8 min at 37°C. HUVECs were cultured in Endothelial Cell Growth Medium BulletKit-2 (EGM-2, Lonza, USA) at 37°C in a humidified atmosphere of 5% CO 2 . EGM-2 was supplemented with the bulletkit growth supplement mixture (Lonza) and 10% fetal bovine serum (FBS; Gibco). The medium was changed every 2 days. When cultures reached about 80% confluence, adherent cells were detached with 0.05% trypsin-0.03% EDTA for 2 min at 37°C, washed with PBS, re-suspended in EGM-2 and plated on tissue culture dishes. For all experiments, we used cells between passages 3 and 5. Passage 3 cells were seeded on glass coverslips and assayed for vWF immunophenotype by immunofluorescence to confirm their stromal nature and to test the degree of purity of the cell cultures.
Experimental design
HUVECs were randomly divided into 5 groups for treatment: blank control; vehicle control (DAPT dissolved in DMSO); TGF-β (10 ng/ml); spironolactone (1 μM)+TGF-β; spironolactone+TGF-β+DAPT (10 μM). HUVECs were exposed to spironolactone 24 h before TGF-β. In selected experiments, cells were treated with DAPT 1 h before spironolactone.
Transwell assay
Cell chemotaxis assay involved 24-well cell culture chambers of 6.5-mm diameter with polycarbonate membrane filters including 8-μm pores (Transwell; Corning). Cells were starved for 12 h, then cell suspension (5×10 4 cells/well) without FBS was added to the upper wells of the inserts. The lower chamber was filled with 600 μL medium supplemented with 2% FBS. Cells were allowed to migrate for 24 h; non-migrated cells were gently wiped with cotton swabs and migrated cells were fixed with ice-cold methanol and stained with crystal violet. The filters were washed with distilled water and images were obtained under an inverted microscope (Olympus). Cells were quantified by manual counting.
Immunofluorescence
For immunofluorescence assay, HUVECs were incubated with agents as indicated on glass slides in 24-well culture plates. After being washed by cold PBS, cells were fixed with 4% paraformaldehyde, sequentially blocked with solution (Beyotime Institute of Biotechnology) containing 1% Triton X-100 and cover-slipped, then treated with primary antibody to CD31 (1:1600 dilution) or vimentin (both Cst: 1:100 dilution) at 4°C in a humid chamber overnight, incubated with Alexa Fluor 488 (for CD31) or Alexa Fluor 594 (for Vimentin) conjugated secondary antibody in the dark for 2 h, then counterstained with Hoechst 33342 for nuclei. Cells were mounted on slides and visualized under a fluorescence microscope (ECLIPSE TI, NIKON).
Western blot analysis
For analysis of protein expression of vimentin, CD31, and Notch1 in HUVECs, cells were homogenized in lysis buffer (150 mol/L NaCl; 2 mmol/L EDTA; 50 mmol/L Tris/HCl; 0.2% Triton X-100; 0.3% IGEPAL, 2 mmol/L EGTA; 1ml/mL PMSF, 10ml/mL protease inhibitors cocktail; 1 ml/mL and 10 ml/mL orthovanadate) and then separated by 10% SDS-polyacrylamide gel electrophoresis. An equal amount of protein (40 μg/well) were loaded in each lane and transferred onto polyvinylidenedifluoride membranes,
Statistical analysis
Data are expressed as mean±SD. Comparison of means involved ANOVA and least significant difference (LSD) test with SPSS 16.0 (Chicago, IL). P < 0.05 was considered statistically significant.
Results
Morphological changes and immunofluorescence of HUVECs
We evaluated morphological alterations in HUVECs (Fig. 1) induced by TGF-β while reversed by spironolactone. As in the process of EndMT, endothelial cells lost their apical--basal polarity and adhesion, for increased migration and invasiveness, and became spindleshaped and elongated. These features were reversed by spironolactone treatment; they lost the prominent filopodia and fibroblastic shape. With DAPT treatment to block the Notch signal pathway, the morphological changes with spironolactone were abrogated. Primary cultured HUVECs were immunostained with antibodies against vWF ( Fig. 1-A) . Treatment with the agents was well tolerated, with no differences in morphological, immunophenotypic or other signs.
Spironolactone inhibits cell migration induced by TGF-β
Cell migration ability was analyzed by transwell chemotactic assay 24 h after migrated cells were evaluated and counted (Fig. 2) . We examined that the number of permeating septum cells in TGF-β group was dramatically increased compared to the control (P <0.01). Spironolactone statistically attenuated the number of migrated cells when pre-cultivated 24 h before TGF-β (P <0.01). The number of migrated cells was increased after disposed with DAPT compared to TGF-β+spironolactone group (P <0.01).
Spironolactone inhibits TGF-β-induced EndMT
In order to determine cell transdifferentiation during EndMT, we examined the change in expression of two biomarkers in each group evaluated by immunofluorescence: upregulation of vimentin and downregulation of CD31. In control HUVECs, Vimentin-positive cells were few, but CD31-positive cells reached the highest intensity (green, Fig. 3 ). TGF-β significantly increased vimentin-positive cells (P<0.01, Fig. 4 ) while reduced the CD31-positive cells (P<0.01, Fig. 3 ). Spironolactone reversed the increased expression in vimentin (P<0.01, Fig.  4 ) and also reversed the lessened expression in CD31 (P<0.01, Fig. 3 ). Spironolactone could significantly inhibit TGF-β-stimulated EndMT incubation of HUVECs in vitro. The results of western blotting showed significant decreased the endothelial-related molecule CD31 was down-regulated with TGF-β treatment (P<0.01, Fig. 5-A) . On the other hand, the mesenchymal-related molecule vimentin was up-regulated induced by TGF-β (P<0.01, Fig. 5-B) . Pre-incubation with spironolactone reversed the TGF-β-stimulated EndMT phenotypic changes, for upregulation of CD31 (P<0.01, Fig. 5-A) and downregulation of vimentin (P<0.01, Fig.s 5-B) . Spironolactone could reverse fibrosis by inhibiting the formation of myofibroblasts, fibers and rebuilding intercellular adhesion sites.
Notch inhibitor suppresses TGF-β-Induced EndMT
To investigate the role of the Notch pathway in fibrosis, transwell analysis showed that spironolactone significantly attenuated TGF-β-induced endothelial cell migration, which could be abrogated with DAPT treatment (P <0.01, Fig. 2) . Therefore, the Notch inhibitor DAPT could abrogate the effect of spironolactone on cell migration. CD31-positive 
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Cellular Physiology and Biochemistry cells were significantly lessened when DAPT was disposed into incubation compared to spironolactone+TGF-β group (P<0.01, Fig. 3 ). In contrast, vimentin-positive cells were increased in number with DAPT than spironolactone+TGF-β group (P<0.01, Fig. 4 ), so the Notch pathway inhibitor attenuated the protective changes stimulated by spironolactone. By the same token, DAPT decreased the TGF-β-increased CD31 protein level (P<0.05, Fig. 5-A) and increased the TGF-β-decreased vimentin level (P<0.05, Fig. 5-B) .
Notch inhibitor reverses EndMT in vitro
Furthermore, to determine whether EndMT can be reversed by blocking Notch signaling pathway, we examined Notch1 protein level. Notch1 protein expression was down-regulated in HUVECs treated with TGF-β (p<0.01, Fig. 5-C) , it was increased with spironolactone treatment (p<0.01) and dramatically down-regulated with DAPT treatment (p<0.01). Therefore, DAPT blocked TGF-β-induced EndMT and reduced the decrease in fibrosis in vitro due to aldosterone receptor antagonism with spironolactone. Inhibiting Notch signaling could cause HUVECs to regain their parental phenotype and play an important role in antifibrosis in vitro with spironolactone treatment.
Discussion
In the present study, we used TGF-β to establish a fibrotic model in HUVECs in vitro; spironolactone inhibited the cell migration, phenotypic transformation and collagen synthesis ability induced by TGF-β. Blocking Notch signaling by a γ-secretase inhibitor, DAPT, significantly altered fibrosis and abrogated the function of spironolactone by increasing the expression of vimentin, in association with the decreased expression of CD31. Finally, we demonstrated that the Notch pathway was closely related to TGF-β-induced EndMT in cultured HUVECs and probed related mechanisms underlying the anti-fibrotic action of spironolactone.
EndMT counts about 10 percent sources of myofibroblasts during the development of cardiac, kidney and pulmonary fibrosis. EndMT is a complex biological process whereby endothelial cells lose their specific markers and acquire a mesenchymal or myofibroblastic phenotype, acquire invasive and migratory properties and express mesenchymal cell products such as α-SMA and type I collagen [1, 18] . In vivo, labeled endothelial cells scattered throughout the fibrotic area expressed multiple myofibroblastic phenotypes in mice with aortic banding to induce myocardial fibrosis [19] . Although transformation of EndMT is often linked to fibrosis and adverse consequences, the primary function of fibrosis in tissue could be repair; for example, myocardial infarction is in fact beneficial [20] . However, EndMT has a critical role during malignant transformation and tumor progression, endowing cancer cells with invasive and metastatic properties [21] .
TGF-β is the key factor regulating the EndMT, which increases the production of extracellular matrices and promotes the fibrosis of cardiac and renal tissues [22] . TGF-β can induce endothelial cells to undergo EndMT in mouse cardiac-fibrosis models [18] . In primary cultured HUVECs, we found evidence of mesenchymal-specific cells associated with increased related protein expression dependent on TGF-β, which led to increased fibrosis. Our cells stimulated with TGF-β and treated with the aldosterone receptor-antagonist spironolactone showed a progressive loss and eventual disappearance of endothelial cell markers, including CD31, and a parallel acquisition of mesenchymal-derived cell markers such as vimentin, which suggested that spironolactone could abrogate the TGF-β-stimulated EndMT in vitro.
Spironolactone, at a dosage which does not disrupt patient's electrolyte and waterretention balance, inhibited myocardial fibrosis, including left ventricular hypertrophy (LVH) [23] . Spironolactone does not affect basal collagen expression, so it is a safe antifibrotic agent [24] . Consistent with these findings, low or high doses of spironolactone could prevent myocardial fibrosis in rats with unilateral renal ischemia or hyperaldosteronism [13] . Fibrosis in Alport syndrome could be effectively ameliorated with spironolactone therapy, thereby avoiding excessive ECM and, consequently, may delay the evolution of progression of renal fibrosis mediated by the TGF-β pathway [25] . Thus, the protective effects of spironolactone are mediated to a large extent by its ability to reverse differentiation and inhibit the subsequent ability of these cells to synthesize collagen, regardless of their origin [26] . Spironolactone plays a crucial role in inhibiting the pathogenesis of tissue fibrosis and effectively stimulates increased gene expression via the EndMT by avoiding the transformation to myofibroblasts.
In our cultured HUVEC cells, suppression of the Notch pathway by DAPT pharmacological inhibition of γ-secretase markedly ameliorated phenotypic EndMT changes induced by spironolactone. We used the Notch γ-secretase inhibitor DAPT to block the Notch pathway to determine changes in spironolactone therapy in ameliorating fibrosis in vitro. When the Notch pathway was blocked, HUVECs showed increased mesenchymal-specific cells and regained the protein expression of mesenchymal markers, both inhibited with spironolactone, which supports the Notch signaling pathway participating in the EndMT. Spironolactone treatment ameliorated TGF-β-induced migration, which was reversed with DAPT pretreatment. Notch1 protein expression was significantly upregulated with spironolactone treatment to suppress TGF-β-induced EndMT and was markedly reduced with DAPT pretreatment to block the Notch pathway. Notch signaling has a crucial role in regulating vascular endothelial cell differentiation and functional abilities in TGF-β-induced EndMT, which could be suppressed by spironolactone probably via the overlapped Notch-related cascade response. Spironolactone may have a promising role in preventing and treating fibrosis by modulating the Notch pathway during EndMT especially with TGF-β stimulation.
Our results provide additional knowledge in the field, because considering spironolactone with Notch-activity localization differs from previous reports. The Notch γ-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-β/Smad2/3 signaling pathway activation [24] . Signaling crosstalk between Notch and TGF-β pathways was demonstrated in the early induction of Hey1 expression in Smad3-dependent and Notchindependent or delayed Notch-dependent pathways [8] . Notch signaling is involved in the corneal EndMT process [24] . Notch/Jagged signaling is essential for endothelial function and may contribute to EndMT in embryogenesis and cancer [10] . A high baseline serum level of pro-fibrotic cytokine markers may benefit from spironolactone treatment by limiting ECM turnover and attenuating change in collagen associated with a TGF-β-activated signaling cascade [27] .
In conclusion, our studies are a proof-of-concept of the underlying mechanisms of Notch signaling pathway having biological significance in the EndMT, which would be greatly inhibited by spironolactone. This research may shed new light on new drug regimens for treating EndMT-related fibrosis diseases. Many studies have investigated the vital involvement of the Notch signaling pathway throughout EndMT, but the detailed molecular regulations and the intracellular cascade response activated by spironolactone and TGF-β in the process has not been entirely elucidated. Other interactional mechanisms driven by spironolactone in EndMT need further exploration.
